Moscow: Russia’s Sputnik V COVID-19 vaccine efficacy is above 95 per cent, 42 days after the primary dose and will price lower than $20 for the worldwide market, the National Research Center for Epidemiology and Microbiology and Russian Direct Investment Fund (RDIF) introduced on Tuesday (November 24, 2020).
“The preliminary data on volunteers on the 42nd day after the first dose (equivalent to 21 days after the second dose), when they have already formed a stable immune response, indicates the efficacy rate of the vaccine is above 95%,” learn the official assertion.
The RDIF introduced that the price of the Russian Sputnik V coronavirus vaccine for worldwide markets will be lower than $10 per dose ranging from February 2021, which is lower than $20 for the 2 doses essential to vaccinate one particular person. Notably, the Sputnik V COVID-19 vaccine is a two-dose vaccine.
Also learn | Pfizer remaining evaluation of Phase 3 research signifies COVID-19 vaccine efficacy fee of 95%
“Sputnik V will be two or more times cheaper than foreign vaccines based on mRNA technology with similar efficacy rates,” mentioned the assertion.
This is to be famous that for the Russian residents, vaccination with Sputnik V will be freed from cost.
As per the protocol of Phase III medical trials of the Sputnik V coronavirus vaccine, its interim efficacy is calculated at three statistically important consultant checkpoints – upon reaching 20, 39 and 78 cases of novel coronavirus an infection amongst volunteers, each within the placebo group and within the group that obtained the vaccine.
The second interim evaluation of the Sputnik V vaccine efficacy was carried out on the idea of 39 confirmed cases recognized within the placebo group (31 cases) and within the vaccine group (8 cases). The ratio of the placebo group to the vaccinated group is 1 to three.
Russia mentioned that the subsequent interim knowledge evaluation will be carried out upon reaching the third checkpoint of 78 confirmed coronavirus cases among the many research individuals. Subsequently, the ultimate knowledge evaluation will be accessible by the tip of Phase III medical trials.
Also learn | Moderna says its vaccine is 94.5% efficient in stopping COVID-19
As of Tuesday, greater than 22,000 volunteers have been vaccinated with the primary dose and greater than 19,000 volunteers with the primary and the second dose of the vaccine at 29 medical facilities throughout Russia as a part of the continuing medical trials.
Currently, Phase III medical trials are accredited and are ongoing in Belarus, the UAE, Venezuela and other international locations, in addition to Phase II-III in India.
No surprising opposed occasions have been recognized as a part of the analysis to this point. Although, a few of these vaccinated had short-term minor opposed occasions similar to ache on the injection level and flu-like signs together with fever, weak spot, fatigue, and headache.
“The data demonstrating high efficacy of the Sputnik V vaccine gives us hope that we will soon obtain the most important tool in the fight against the pandemic of the novel coronavirus infection,” mentioned Mikhail Murashko, Russian Health Minister.
Also learn | After Pfizer and Moderna, Oxford-AstraZeneca COVID-19 vaccine will be 90% efficient